Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 11/2013

01-07-2013 | Review Article

Meningococcal Vaccines: Current Issues and Future Strategies

Authors: Amanda C. Cohn, Lee H. Harrison

Published in: Drugs | Issue 11/2013

Login to get access

Abstract

Since the introduction of the first meningococcal conjugate vaccines in 1999, remarkable progress has been made in reducing the morbidity and mortality caused by meningococcal disease. Currently, varying meningococcal conjugate vaccines provide protection against serogroups A, C, Y, and W meningococcal disease. A large impact has been seen after vaccine introduction, particularly in the UK after vaccinating all 1–17 year olds. The introduction of serogroup A conjugate vaccine in the meningitis belt has the potential to control epidemics of disease that disproportionately affect this area of the world. Issues remain that require continued vigilance with disease surveillance and frequent reassessment of vaccine strategies. These issues include duration of protection, potential increases in non-vaccine serogroups, and vaccine safety and potential interference with other routine vaccines. Serogroup B meningococcal vaccines are protein-based vaccines, with the first approved in early 2013. Understanding the potential impact of serogroup B vaccines is critical to developing future meningococcal vaccination strategies.
Literature
1.
Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93(4):341–53.PubMedCrossRef
2.
LaForce M, Ravenscroft N, Mamoudou D, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009;27(Suppl 2):B13–9.CrossRef
3.
Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J Paediatr Child Health. 2001;37(5):S13–9.PubMedCrossRef
4.
Oster P, Lennon D, O’Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23(17–18):2191–6.PubMedCrossRef
5.
Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis. 2009;49(4):597–605.PubMedCrossRef
6.
Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184–91.PubMedCrossRef
7.
Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health. 2002;5(3):220–5.PubMed
8.
Bilukha OO, Rosenstein N, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21.PubMed
9.
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63.PubMedCrossRef
10.
Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–88.PubMedCrossRef
11.
Koumare B, Ouedraogo-Traore R, Sanou I, Yada AA, Sow I, Lusamba PS, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine. 2007;25(Suppl 1):A37–41.PubMedCrossRef
12.
Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13(6):920–3.PubMedCrossRef
13.
Delrieu I, Yaro S, Tamekloe TAS, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE. 2011;6(5):e19513.PubMedCrossRef
14.
Djibo S, Nicolas P, Alonso JM, Djibo A, Couret D, Riou JY, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000. Trop Med Int Health. 2003;8(12):1118–23.PubMedCrossRef
15.
Annual epidemiological report on communicable diseases in Europe. In: Control CfDPa, editor. Stockholm; 2009.
16.
Ramsay M, Kaczmarski E, Rush M, Mallard R, Farrington P, White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev. 1997;7(4):R49–54.PubMed
17.
Caugant DA, Hoiby EA, Magnus P, Scheel O, Hoel T, Bjune G, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994;32(2):323–30.PubMed
18.
Caugant DA, Maiden MC. Meningococcal carriage and disease—population biology and evolution. Vaccine. 2009;27(Suppl 2):B64–70.PubMedCrossRef
19.
Lakshman R, Jones I, Walker D, McMurtrie K, Shaw L, Race G, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child. 2001;85(5):391–7.PubMedCrossRef
20.
Bramley JC, Hall T, Finn A, Buttery RB, Elliman D, Lockhart S, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19(20–22):2924–31.PubMedCrossRef
21.
MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283(21):2795–801.PubMedCrossRef
22.
Choo S, Zuckerman J, Goilav C, Hatzmann E, Everard J, Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine. 2000;18(24):2686–92.PubMedCrossRef
23.
Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28(2):86–91.PubMedCrossRef
24.
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299(2):173–84.PubMedCrossRef
25.
Centers for Disease Control and Prevention. Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52–4.
26.
Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365–7.PubMedCrossRef
27.
Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23(32):4097–100.PubMedCrossRef
28.
MacNeil JR, Cohn AC. Meningococcal vaccine effectiveness. Boston: Pediatric Academic Society Annual Meeting; 2012.
29.
Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829–31.PubMedCrossRef
30.
Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357(9251):195–6.PubMedCrossRef
31.
Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–6.PubMedCrossRef
32.
Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–7.PubMedCrossRef
33.
CDC. National and state vaccination coverage among adolescents aged 13–17 years—United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671–7.
34.
Clark TA, Stern EJ, Pondo T, Arnold K, Harrison L, Vello M, Hollick R, Mayer L, Schmink S, Hatcher C, Theodore J, Harcourt B, Dolan J, Stephens D, Messonnier N. The effect of quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. 16th international pathogenic Neisseria conference, Rotterdam; 2008.
35.
Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006;43(11):1387–94.PubMedCrossRef
36.
Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745–52.PubMedCrossRef
37.
Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186(9):1353–7.PubMedCrossRef
38.
Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24(2):128–31.PubMedCrossRef
39.
Sakou II, Tzanakaki G, Tsolia MN, Sioumala M, Barbouni A, Kyprianou M, et al. Investigation of serum bactericidal activity in childhood and adolescence 3–6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine. 2009;27(33):4408–11.PubMedCrossRef
40.
Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19(8):1126–30.PubMedCrossRef
41.
Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006;193(6):821–8.PubMedCrossRef
42.
Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents. Hum Vaccine. 2010;6(11):881–7.CrossRef
43.
Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.PubMed
44.
Marshall GS, Blatter M, Marchant C, Aris E, Mesaros N, Miller JM. Antibody persistence for up to 5 years after a fourth dose of haemophilus influenzae type B and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (Hibmency-TT) given at 12–15 months of age. Pediatr Infect Dis J. 2013.
45.
Caron F, du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455–63.PubMedCrossRef
46.
Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA. 1997;94(1):271–6.PubMedCrossRef
47.
Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era–United States, 2000–2005. J Infect Dis. 2010;201(8):1208–24.PubMedCrossRef
48.
Harrison LH, Jolley KA, Shutt KA, Marsh JW, O’Leary M, Sanza LT, et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis. 2006;193(9):1266–74.PubMedCrossRef
49.
Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis. 2002;185(11):1596–605.PubMedCrossRef
50.
Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–27.PubMedCrossRef
51.
Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710–6.PubMedCrossRef
52.
Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007–2009. Emerg Infect Dis. 2012;18(1):63–70.PubMedCrossRef
53.
Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36.PubMedCrossRef
54.
Guillain–Barre syndrome among recipients of Menactra meningococcal conjugate vaccine–United States, June–July 2005. MMWR Morb Mortal Wkly Rep. 2005;54(40):1023–5.
55.
Tully J, Viner RM, Coen PG, Stuart JM, Zambon M, Peckham C, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332:445–50.PubMedCrossRef
56.
Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep. 2011;60(40):1391–2.
57.
Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12(10):757–64.PubMedCrossRef
58.
Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354–63.PubMedCrossRef
59.
Tondella MLC, Popovic T, Rosenstein NE, Lake DB, Mayer L, Perkins B, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol. 2000;38(8):2402–7.
60.
Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J Infect Dis. 2000;182(4):1169–76.PubMedCrossRef
61.
Vicente D, Esnal O, Michaus L, Lopez de Goicoechea MJ, Cisterna R, Perez-Trallero E. Prevalence of genosubtypes (PorA types) of serogroup B invasive meningococcus in the north of Spain from 2000 to 2003. J Med Microbiol. 2005;54(Pt 4):381–4.PubMedCrossRef
62.
Jansen KU, McNeil LK, Dragalin V, Anderson AS, Hoiseth SK, Arora A, et al. Bivalent recombinant LP2086 vaccine to provide broad protection against Neisseria meningitidis B disease: immunological correlates of protection and how to assess coverage against invasive MnB strains. 16th International pathogenic Neisseria conference, Rotterdam; 2008.
63.
Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086–93.PubMedCrossRef
64.
Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–37.PubMedCrossRef
65.
Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis. 2011;5(9):e1302.PubMedCrossRef
66.
Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis. 2009;199(9):1360–8.PubMedCrossRef
67.
Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–5.PubMedCrossRef
68.
Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609–17.PubMedCrossRef
69.
Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82.PubMedCrossRef
70.
Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29–30):4739–44.PubMedCrossRef
71.
Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31(23):2638-46
72.
Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2013. p. 388–418.
73.
Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull T. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. doi:10.​1097/​INF.​0b013e318279ac38​.
Metadata
Title
Meningococcal Vaccines: Current Issues and Future Strategies
Authors
Amanda C. Cohn
Lee H. Harrison
Publication date
01-07-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 11/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0079-2

Other articles of this Issue 11/2013

Drugs 11/2013 Go to the issue

Erratum

Erratum to: Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias

Review Article

Adverse Effects of Immunosuppressant Drugs upon Airway Epithelial Cell and Mucociliary Clearance: Implications for Lung Transplant Recipients

Adis Drug Evaluation

Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion

Adis Drug Evaluation

Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years

Systematic Review

Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials

Adis Drug Evaluation

Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma